| Tumour necrosis factor inhibitor-related lupus: safety of switching agents. | |
| | |
MedLine Citation:
|
PMID: 20119843 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
An increase in reports of systemic lupus erythematosus (SLE) related to tumour necrosis factor inhibitor (TNFi) therapy has recently been highlighted. We report new-onset SLE in a 22-year-old woman after 13 months of infliximab for ankylosing spondylitis (AS). Lupus symptoms promptly resolved and serologic abnormalities improved after infliximab was ceased. A flare of AS symptoms after 2 months prompted cautious introduction of an alternative TNFi, etanercept. At 14 months follow-up, neither clinical nor serologic flare of lupus had occurred. To our knowledge, this is the third reported case of infliximab-related lupus that did not recur on switching to an alternative TNFi. |
| | |
Authors:
|
Jessica M T Luong; Boon T Tan; Russell R C Buchanan; Lionel Schachna |
Related Documents
:
|
12468063 - Pancarditis as initial presentation of systemic lupus erythematosus. 15115143 - Cerebral infarction and cerebral salt wasting syndrome in a patient with tuberculous me... 11991483 - Symptomatic bipartite medial cuneiform in an adult athlete: a case report. |
Publication Detail:
|
Type: Case Reports; Journal Article Date: 2010-02-02 |
Journal Detail:
|
Title: Clinical rheumatology Volume: 29 ISSN: 1434-9949 ISO Abbreviation: Clin. Rheumatol. Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-03-23 Completed Date: 2010-07-28 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8211469 Medline TA: Clin Rheumatol Country: Germany |
Other Details:
|
Languages: eng Pagination: 551-3 Citation Subset: IM |
Affiliation:
|
Department of Rheumatology, Austin Health, PO Box 5555, Heidelberg, VIC, 3084, Australia. jessica.luong@austin.org.au |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antibodies, Monoclonal / pharmacology* Antirheumatic Agents / pharmacology Autoimmunity DNA / metabolism Female Humans Immunoglobulin G / pharmacology* Inflammation Lupus Erythematosus, Systemic / blood, drug therapy* Quality of Life Receptors, Tumor Necrosis Factor Spondylitis, Ankylosing / blood, drug therapy* Time Factors Tumor Necrosis Factor-alpha / antagonists & inhibitors* |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 0/infliximab; 185243-69-0/TNFR-Fc fusion protein; 9007-49-2/DNA |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler's syndrome: a c...
Next Document: The 5'UTR of CCA1 includes an autoregulatory cis element that segregates between light and circadian...